[1]惠建萍,马小兵,沈舒文,等.解毒化瘀法治疗毒瘀交阻型胃癌前病变临床研究[J].陕西中医药大学学报,2019,(03):097-101.[doi:10.13424/j.cnki.jsctcm.2019.03.026]
 Hui Jianping,Ma Xiaobing Shen Shuwen Du Xiaoquan Zhang Yaozhi.Clinical Study on the Treatment of Precancerous Lesions of Gastric Cancer with Toxin - Stasis Interaction by “ Detoxification and Phlegm Resolving Method”[J].Journal of Shaanxi University of Traditional Chinese Medicine,2019,(03):097-101.[doi:10.13424/j.cnki.jsctcm.2019.03.026]
点击复制

解毒化瘀法治疗毒瘀交阻型胃癌前病变临床研究 ()
分享到:

《陕西中医药大学学报》[ISSN:2096-1340/CN:61-1501/R]

卷:
期数:
2019年03期
页码:
097-101
栏目:
临床研究
出版日期:
2019-05-30

文章信息/Info

Title:
Clinical Study on the Treatment of Precancerous Lesions of Gastric Cancer with Toxin - Stasis Interaction by “ Detoxification and Phlegm Resolving Method”
文章编号:
2096-1340(2019)03-0097-05
作者:
惠建萍马小兵沈舒文杜晓泉张耀之
1.陕西中医药大学,陕西咸阳712046;2.陕西中医药大学附属医院,陕西咸阳712000
Author(s):
Hui Jianping 1 2 Ma Xiaobing 1 Shen Shuwen 1 Du Xiaoquan 2 Zhang Yaozhi 1
1. Shaanxi University of Chinese Medicine, Xianyang China, 712046; 2. Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang China, 712000
关键词:
解毒化瘀法胃癌前病变临床研究
Keywords:
detoxification and phlegm resolving method PLGC clinical research
分类号:
R753.2
DOI:
10.13424/j.cnki.jsctcm.2019.03.026
文献标志码:
A
摘要:
目的观察解毒化瘀法治疗毒瘀交阻型胃癌前病变(PLGC)的临床疗效?方法将190例PLGC患者随机分为治疗组及对照组各95例,治疗组91例予以特定处方用药煎剂治疗,对照组87例予以维酶素片口服,2月为1疗程,3个疗程后比较两组患者症状积分变化,评价临床疗效?结果治疗组有效率82.42%,对照组有效率68.97%,治疗组疗效优于对照组,其差异有统计学意义(P<0.05)?治疗前后症状积分比较,治疗组在改善胃痛?痞胀?灼热?纳差?嘈杂等症状疗效优于对照组,差异有统计学意义(P<0.01,P<0.05)?结论解毒化瘀法对毒瘀交阻型PLGC患者的临床症状有明显改善作用,有待进一步推广应用?
Abstract:
Objective To observe the clinical effect of “ Detoxification and Phlegm Resolving Method” in the treatment of Precancerous Lesions of Gastric Cancer ( PLGC) . Methods 190 patients with PLGC were randomly divided into treatment group and control group. The treatment group was treated with specific prescription decoction, while the control group was treated with vermectin tablets orally. The course of treatment was 2 months. After 3 courses, the changes of symptom scores were compared between the two groups, and the clinical efficacy was evaluated. Results The effective rate of the treatment group was 82. 42%, and that of the control group was 68. 97%. The curative effect of the treatment group was better than that of the control group, and the difference was statistically significant ( P > 0. 05) . Comparing the scores of symptoms before and after treatment, the curative effect of the treatment group was better than that of the control group in improving the symptoms of stomachache, swelling, burning, nausea, noise, etc. ( P < 0. 01, P < 0. 05) .Conclusion “ Detoxification and phlegm resolving method” has a significant improvement effect on the clinical symptoms of PLGC patients with toxin - stasis interaction, which needs further promotion and application.

参考文献/References:

[1] VENERITO M, LINK A, ROKKAS T A. Gastric cancer clinical and epidemiological aspects [ J] . Helicobacter,2016,21( SI) : 39 -44.
[2]林依娜.中药治疗慢性萎缩性胃炎临床疗效的Meta分析[J].陕西中医药大学学报,2018,41(4):52-58.
[3]房静远,杜奕奇,刘文忠,等.中国慢性胃炎共识意见(2017年,上海)[J].胃肠病学,2017,22(11):670-687.
[4]李军祥,陈?,吕宾,等.慢性萎缩性胃炎中西医结合诊疗共识意见(2017年)[J].中国中西医结合消化杂志,2018,26(2):121-131.
[5]王捷虹,沈舒文,刘力,等.中医辨证治疗胃癌前期病变的临床观察与体会[J].辽宁中医杂志,2013,40(1):105-107.
[6]沈舒文,惠建萍,刘力,等.胃癌前病变虚实标本兼治的临床疗效研究[J].世界科学技术(中医药现代化),2012,17(1):1247-1251.
[7]伏沿蓉,张佳,王捷虹,等.慢性萎缩性胃炎中医治疗进展[J].陕西中医药大学报,2017,40(4):134-136.
[8]惠建萍,沈舒文,刘力,等.从“毒瘀交阻”理论辨治胃癌前病变的思路与方法[J].世界科学技术(中医药现代化),2012,17(1):1270-1272.
[9]张万岱.导言:加强胃癌前病变的监测和防治研究[J].医学与哲学,2015,36(11B):9.
[10]沈舒文,惠建萍,宇文亚,等. Study on Canceration Lawof Gastric Mucosal Dysplasia Based on Syndromes of Chinese Medicine[ J] . Chinese Journal of Integrative Medicine,2011, ( 5) :346 -350.
[11]杨沙,段灿灿,晏仁义,等.基于网络药理学的半枝莲抗肿瘤活性成分及整合作用机制研究[J].中草药,2018,49(15):3471-3482.
[12]张餠,李忠.枸橘苷对胃癌细胞抑制作用及其机制研究[J].中国病理生理杂志,2017,33(9):1637-1642.
[13]赵勤,卫昊,胡锐,等.朱砂七总蒽醌对S180荷瘤小鼠凋亡基因表达的影响[J].天津中医药,2013,30(10):609-611
[14]崔奕,郑亮.郑亮教授论治慢性萎缩性胃炎临证撷要[J].陕西中医药大学学报,2018,41(1):18-20.
[15]张德英,侯卓成,李卫强.中医药治疗胃癌前病变研究进展[J].辽宁中医杂志,2016,43(1):207-210.

相似文献/References:

[1]宋健袁敏惠 崔冰慧 褚宇鹏 孟凯强 黄毓娟 惠建萍刘争辉 王捷虹 沈舒文.金果胃康胶囊对PLGC大鼠Wnt/Lgr5 信号通路的干预研究[J].陕西中医药大学学报,2022,(05):102.[doi:10.13424/j.cnki.jsctcm.2022.05.020 ]
 SONG Jian YUAN Minhui CUI Binghui CHU Yupeng MENG Kaiqiang HUANG Yujuan HUI Jianping LIU Zhenghui WANG Jiehong SHEN Shuwen.Intervention of Jinguo Weikang Capsule onWnt/Lgr5 Signal Pathway in PLGC Rats[J].Journal of Shaanxi University of Traditional Chinese Medicine,2022,(03):102.[doi:10.13424/j.cnki.jsctcm.2022.05.020 ]
[2]惠建萍张耀之刘海涛王军李龙梅.金果胃康胶囊调控胃癌前病变大鼠HSP27及MAD2表达研究[J].陕西中医药大学学报,2023,(06):060.[doi:10.13424/j.cnki.jsctcm.2023.06.010]
 HUI JianpingZHANG YaozhiLIU HaitaoWANG JunLI LongmeiSHEN Shuwen.Study on the Regulation of HSP27 and MAD2 Expression in Gastric???? Precancerous Lesions in Rats by Jinguo Weikang Capsule[J].Journal of Shaanxi University of Traditional Chinese Medicine,2023,(03):060.[doi:10.13424/j.cnki.jsctcm.2023.06.010]

更新日期/Last Update: 2019-05-29